Last updated: February 5, 2026
Clinical Trials Update, Market Analysis and Projection for TISSEEL
What is the current status of TISSEEL's clinical trials?
TISSEEL, a fibrin sealant developed by CSL Behring, is approved for multiple surgical and medical uses, including hemostasis and tissue sealing. The drug has undergone various phases of clinical testing to expand indications and assess safety and efficacy.
Current Clinical Trials
- Approved Indications: TISSEEL is approved in numerous countries for use in cardiothoracic, vascular, and general surgeries.
- Ongoing Trials: Several late-phase trials focus on new indications, including its use in gastrointestinal, ENT, and gynecological surgeries.
| Trial ID |
Phase |
Focus |
Status |
Estimated Completion |
Sponsor |
| NCT03386302 |
III |
Spinal surgeries |
Recruiting |
Q4 2024 |
CSL Behring |
| NCT04608544 |
II |
Use in obstetric hemorrhage |
Recruiting |
Q2 2025 |
Academic/CSL |
| NCT04139946 |
III |
Bleeding control in trauma |
Active |
Q3 2024 |
Multi-center |
Most trials aim to broaden indications to include traumatic bleeding and specific surgical procedures. No recent phase I or II trials suggest significant pipeline shift away from existing approval lines.
How does TISSEEL compare with competitors?
Major competitors include Baxter's FEIBA, Ethicon's TachoSil, and Cytomedix's Surgiflo.
| Metric |
TISSEEL |
TachoSil |
Surgiflo |
| Composition |
Fibrinogen + Thrombin |
Fibrinogen + Collagen |
Gelform + Thrombin |
| Approved indications |
Multiple surgeries |
Surgical bleeding |
Surgical bleeding |
| Cost per unit (approx.) |
$300-$600 |
$200-$500 |
$200-$400 |
| Market share (estimated) |
30-40% |
20-30% |
10-15% |
TISSEEL maintains a leading position due to established safety, extensive clinical data, and broad applicability.
What is the current market landscape?
Global Market Size and Trends
The global surgical sealants market was valued at approximately $1.4 billion in 2022 [1]. An average compound annual growth rate (CAGR) of about 6% is projected through 2028, driven by increasing surgical procedures and adoption of bleeding management products.
Adoption Drivers
- Surgeon's preference for secure hemostasis tools.
- New applications in minimally invasive and robotic surgeries.
- Growing number of surgeries globally.
Regional Breakdown
| Region |
Market Size (2022) |
CAGR |
Key Factors |
| North America |
$600 million |
5.5% |
High procedural volume, regulatory approvals |
| Europe |
$400 million |
6.2% |
Aging population, advanced healthcare infrastructure |
| Asia-Pacific |
$250 million |
7.8% |
Increasing surgical procedures, expanding healthcare access |
What are the projections for TISSEEL's market performance?
Short-Term Outlook (2023-2025)
- Expect steady growth of 5-7% annually.
- Expansion into additional indications, notably trauma and obstetrics.
- Increased sales volume in hospitals with expanding surgical procedures.
Long-Term Outlook (2026-2030)
- Market size projected to surpass $2 billion by 2030.
- New indications, including Ischemic and vascular surgeries, potentially contributing to growth.
- Potential for biosimilar or generic entrants affecting pricing and market share.
What are key factors influencing TISSEEL's future?
- Regulatory Approvals: Approval of new indications, especially in emerging markets, will expand sales.
- Competitive Landscape: Innovations from rivals or biosimilars may threaten market share.
- Clinical Evidence: Positive results from ongoing trials can support label expansion.
- Pricing and Reimbursement: Reimbursement policies across regions will impact utilization.
Summary
TISSEEL remains a dominant fibrin sealant with an established clinical and commercial footprint. Its ongoing trials aim to extend its use, while market growth is driven by increasing surgical procedures and expanding indications. Competition, regulatory landscape, and reimbursement policies will influence its market trajectory.
Key Takeaways
- TISSEEL's latest clinical trials focus on new indications like trauma and obstetrics; most are in late phases.
- It faces competition from TachoSil and Surgiflo, with market shares estimated at 30-40%.
- The global surgical sealants market is growing at approximately 6%, expected to reach over $2 billion in the next decade.
- Future growth depends on regulatory approvals, positive trial results, and competitive dynamics.
- Pricing strategies and reimbursement policies will significantly impact sales expansion.
FAQs
Q1: What new indications is TISSEEL exploring?
A: Clinical trials are assessing its use in trauma management and obstetric hemorrhage.
Q2: How does TISSEEL compare cost-wise with competitors?
A: It typically costs between $300 and $600 per unit, higher than some competitors such as TachoSil but justified by broader approval and clinical data.
Q3: Which regions are the main markets for TISSEEL?
A: North America, Europe, and Asia-Pacific are the leading regions, with North America holding the largest share.
Q4: What factors could slow TISSEEL’s growth?
A: Competition from biosimilars, regulatory hurdles, and reimbursement challenges may impede sales.
Q5: When is TISSEEL expected to see significant market expansion?
A: If approvals are obtained for new indications and reimbursement policies support its use, significant growth could occur between 2026 and 2030.
References
[1] MarketsandMarkets, "Surgical Sealants and Hemostats Market," 2022.
